7
Participants
Start Date
June 23, 2015
Primary Completion Date
August 15, 2019
Study Completion Date
August 15, 2019
Lirilumab
3 mg/kg by vein given on Day 1 of each 28 day cycle.
Rituximab
375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
M.D. Anderson Cancer Center
OTHER